FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W171339041> ?p ?o ?g. }

• W171339041 abstract "Human fetuin-A (alpha 2 -Heremans Schmid glycoprotein) has been identified as the most potent circulating inhibitor of vascular and soft-tissue calcification. We aimed to investigate the relationship between the serum fetuin-A level and the progression of aortic valve calcification (AVC) assessed by retrospectively ECG-gated Multislice Spiral Computed Tomography (MSCT) in patients with calcific aortic valve disease. A prospective study in 77 non-dialyzed patients (mean age 70 ± 8 years) with echocardiographically proven aortic valve disease was performed. In all patients serum fetuin-A levels were measured by nephelometry (BNII, Dade Behring Holding, Liederbach, Germany) using a polyclonal rabbit anti-human antibody against fetuin-A. For quantification of AVC all patients underwent 16-slice MSCT (Sensation 16, Siemens, Forchheim, Germany with scan parameters as follows: 420ms tube rotation time, 12× 0.75mm collimation, tube voltage 120KV). After a mean follow-up of 12.6 ± 1.4 months a second non-enhanced MSCT examination for quantification of AVC was performed. Images were reconstructed at 60% of the RR interval. AVC was assessed using Agatston AVC score. In multifactorial analysis of covariance including fetuin-A levels, baseline AVC score, the covariables sex, age, body mass index, C-reactive protein, glomerular filtration rate, serum lipids, diabetes, smoking status and hypertension, only fetuin-A levels revealed a significant effect on the progression of AVC (p<0.001). Post-hoc analysis demonstrated that patients with baseline fetuin-A levels lower than the median of the cohort (0.72g/l) showed a significantly higher increase of AVC scores (34.6 ± 31.4%, n=39) than patients with fetuin-A levels larger than the median (10.0 ± 11.2%, p<0.001) despite comparable baseline AVC scores. Vice versa, patients with progressive AVC > 10% (n=48, 62%) had lower fetuin-A serum levels at baseline than non-progressors (n=29, 38%; 0.66±0.13g/L versus 0.82±0.11 g/L, p<0.001). The present study suggests that low fetuin-A serum levels indicating systemic calcification inhibitor deficiency were associated with increased progression of AVC independently of the renal function." @default.
• W171339041 created "2016-06-24" @default.
• W171339041 creator A5007105515 @default.
• W171339041 creator A5010099547 @default.
• W171339041 creator A5010370700 @default.
• W171339041 creator A5017710588 @default.
• W171339041 creator A5027966081 @default.
• W171339041 creator A5052533904 @default.
• W171339041 creator A5071670582 @default.
• W171339041 date "2008-10-28" @default.
• W171339041 modified "2023-09-26" @default.
• W171339041 title "Abstract 6145: Low Fetuin-A Concentrations Predict the Progression of Aortic Valve Calcification in Non-Dialyzed Patients" @default.
• W171339041 doi "https://doi.org/10.1161/circ.118.suppl_18.s_1070-b" @default.
• W171339041 hasPublicationYear "2008" @default.
• W171339041 type Work @default.
• W171339041 sameAs 171339041 @default.
• W171339041 citedByCount "0" @default.
• W171339041 crossrefType "journal-article" @default.
• W171339041 hasAuthorship W171339041A5007105515 @default.
• W171339041 hasAuthorship W171339041A5010099547 @default.
• W171339041 hasAuthorship W171339041A5010370700 @default.
• W171339041 hasAuthorship W171339041A5017710588 @default.
• W171339041 hasAuthorship W171339041A5027966081 @default.
• W171339041 hasAuthorship W171339041A5052533904 @default.
• W171339041 hasAuthorship W171339041A5071670582 @default.
• W171339041 hasConcept C126322002 @default.
• W171339041 hasConcept C159641895 @default.
• W171339041 hasConcept C164705383 @default.
• W171339041 hasConcept C188816634 @default.
• W171339041 hasConcept C2780309369 @default.
• W171339041 hasConcept C2780714102 @default.
• W171339041 hasConcept C2781414266 @default.
• W171339041 hasConcept C71924100 @default.
• W171339041 hasConcept C90924648 @default.
• W171339041 hasConceptScore W171339041C126322002 @default.
• W171339041 hasConceptScore W171339041C159641895 @default.
• W171339041 hasConceptScore W171339041C164705383 @default.
• W171339041 hasConceptScore W171339041C188816634 @default.
• W171339041 hasConceptScore W171339041C2780309369 @default.
• W171339041 hasConceptScore W171339041C2780714102 @default.
• W171339041 hasConceptScore W171339041C2781414266 @default.
• W171339041 hasConceptScore W171339041C71924100 @default.
• W171339041 hasConceptScore W171339041C90924648 @default.
• W171339041 hasIssue "suppl_18" @default.
• W171339041 hasLocation W1713390411 @default.
• W171339041 hasOpenAccess W171339041 @default.
• W171339041 hasPrimaryLocation W1713390411 @default.
• W171339041 hasRelatedWork W1532438777 @default.
• W171339041 hasRelatedWork W1984923792 @default.
• W171339041 hasRelatedWork W2027697512 @default.
• W171339041 hasRelatedWork W2131787811 @default.
• W171339041 hasRelatedWork W2142754305 @default.
• W171339041 hasRelatedWork W2309125640 @default.
• W171339041 hasRelatedWork W2887393115 @default.
• W171339041 hasRelatedWork W4242221205 @default.
• W171339041 hasRelatedWork W4281732451 @default.
• W171339041 hasRelatedWork W4281786641 @default.
• W171339041 hasVolume "118" @default.
• W171339041 isParatext "false" @default.
• W171339041 isRetracted "false" @default.
• W171339041 magId "171339041" @default.
• W171339041 workType "article" @default.